To evaluate the effectiveness of disitamab vedotin (RC-48) in a patient with HER2-low metastatic breast cancer after multiple prior systemic therapies, including specific treatments and their outcomes.
Key Findings:
RC-48 treatment led to marked regression of chest-wall cutaneous lesions, indicating potential clinical benefit.
Tumor markers showed partial biochemical improvement, suggesting a positive response.
Time to treatment failure (TTF) was 4.6 months, which should be interpreted in the context of overall treatment response.
Interpretation:
The case highlights the potential clinical benefit of RC-48 in HER2-low metastatic breast cancer and emphasizes the critical need for repeat biopsies to assess HER2 status during disease evolution.
Limitations:
Survival outcomes should be interpreted cautiously due to the patient's decline of further therapy after a COVID-19-associated septic shock event, which may have influenced treatment decisions.
This is a single case study, limiting generalizability to broader patient populations.
Conclusion:
Disitamab vedotin (RC-48) may offer a meaningful therapeutic option for selected patients with HER2-low metastatic breast cancer, underscoring the importance of dynamic HER2 status assessment.
